Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
about
Current approaches for optimizing the benefit of biologic therapy in ulcerative colitisPredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseOptimizing biologic treatment in IBD: objective measures, but when, how and how often?How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsTherapeutic drug monitoring in inflammatory bowel diseasePharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategiesTherapeutic drug monitoring in patients with inflammatory bowel diseaseClinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseasePharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.Second Korean guidelines for the management of ulcerative colitis.Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.Management of Crohn's disease in poor responders to adalimumab.Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.TNF blocking therapies and immunomonitoring in patients with inflammatory bowel diseasePharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.Biologic concentration testing in inflammatory bowel disease.Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases.Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.Update on the Medical Management of Crohn's Disease.Utilisation of anti-TNF levels in a UK tertiary IBD centre.Use of anti-TNF drug levels to optimise patient management.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice.Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis.Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.Recent trends and future directions for the medical treatment of ulcerative colitis.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
P2860
Q26745712-85E94B30-ED5C-4C99-9E06-96F1D39E6A25Q26745721-634A19A9-0F13-494E-A65E-205CB57AAD75Q26775064-22389AA6-C709-401E-A5B4-185FD0C11F74Q26777409-1EFA95F0-99B6-46F6-8F40-50F418C075C2Q26785537-0BA86E3F-8F8E-4526-947D-DC01B98DB23AQ26852729-090DAADA-61B0-4F91-A091-9E0CBBDEABB4Q33758469-B6CEAEC5-BDF0-4A18-ADF6-A49E86D0F133Q35140715-772ECF4D-D4B3-428B-9A4C-F27AA6CA6F3AQ36089928-268231CA-7A32-4D56-9497-F279CD2B6A20Q36150080-5338C458-2D92-4DED-863C-885C4228581CQ37275504-C5AED58E-B497-4C39-8404-AABA133E0D34Q37523503-74436F1D-B23B-460D-A2B2-AFABFB44ACD1Q37624487-6C52D5FA-A66A-47CA-BDA4-7AD4FFF33C11Q37662503-049C4772-CF43-4B78-8F51-EA713886A6E9Q37672250-62210F7D-F270-44F4-9B20-905E11667307Q37708656-2A8988C5-89C3-4FF6-8575-51F131904B99Q38193349-6809C659-F16D-4E11-BAE5-980C09FC0B48Q38206507-6E06F1B2-6E2E-4E44-BE8E-4DF33B3B363AQ38211991-3316E4E3-F8AF-4DEC-B583-D4A7619F53EAQ38319306-B544D3D9-50E9-49DC-A48D-6FAD94E44B0BQ38323592-8C176BAE-E53B-4340-92AD-682D1EB86599Q38364461-AED0B901-BEAA-4C85-8345-B3A7C4185F3FQ38364464-1F59D833-1FB3-4B57-947C-FD2A0F7D9DD2Q38365049-2516E6CB-518F-4AEC-AF9C-E51DA3E96235Q38435506-27C588E2-DA9B-4BCC-9A66-0EFB439449CAQ38462602-4C3AE305-C223-4641-AEE8-3932D10CDEFAQ38585634-537DDD3B-D7C7-488E-B3B1-FBC60C503460Q38608944-4E27F890-464B-4BBC-A621-2A156DF69D43Q38608951-902042A0-7D7B-4B30-833C-441A29F40C54Q38630959-319560B6-0369-4D03-B158-5434596A3C24Q38633561-E5CC63CF-206D-41D1-86CD-33B68244D112Q38673082-9D4763BD-7934-4060-9E4F-75D9A2033A0CQ38678882-1ECDA8AA-3E85-4023-9320-D2F55D26E135Q38695300-F06EFDC7-8269-4E5C-8DEC-3DA2E926B0D4Q38702414-E819D0A0-526F-4EC3-8D88-482F838AFA6EQ38719570-A280B755-7D86-4796-B180-1AF0BFBF03F9Q38798678-ECC9FB1B-B568-4E4E-B879-147614DEF09AQ38814451-C2FE2674-BC07-43B4-A53B-15AC872C6DECQ38815035-F1A6A68E-4F0A-4FA0-B50F-04C243C1DB6DQ38822920-7FCFD7EF-67F1-4432-8C32-1E5B8EB3C796
P2860
Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Association between pharmacoki ...... h inflammatory bowel diseases.
@en
Association between pharmacoki ...... h inflammatory bowel diseases.
@nl
type
label
Association between pharmacoki ...... h inflammatory bowel diseases.
@en
Association between pharmacoki ...... h inflammatory bowel diseases.
@nl
prefLabel
Association between pharmacoki ...... h inflammatory bowel diseases.
@en
Association between pharmacoki ...... h inflammatory bowel diseases.
@nl
P2093
P50
P1476
Association between pharmacoki ...... th inflammatory bowel diseases
@en
P2093
Amelie Moreau
Christian Genin
Emilie Del Tedesco
Jean Marc Phelip
Laurent Peyrin-Biroulet
Melanie Rinaudo
P304
P356
10.1016/J.CGH.2013.07.010
P407
P577
2013-07-23T00:00:00Z